MCID: GLL048
MIFTS: 52

Glial Tumor

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Glial Tumor

MalaCards integrated aliases for Glial Tumor:

Name: Glial Tumor 58
Glioma 58

Characteristics:

Orphanet epidemiological data:

58
glial tumor
Prevalence: 1-9/100000 (United States),1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

MESH via Orphanet 45 D005910
UMLS via Orphanet 72 C0017638
Orphanet 58 ORPHA182067

Summaries for Glial Tumor

MalaCards based summary : Glial Tumor, also known as glioma, is related to diffuse midline glioma, h3 k27m-mutant and gliosarcoma. An important gene associated with Glial Tumor is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Midazolam and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and t cells, and related phenotypes are Increased Akt phosphorylation after EGF stimulation and cellular

Wikipedia : 74 Glial tumor is a general term for numerous tumors of the central nervous system, including astrocytomas,... more...

Related Diseases for Glial Tumor

Diseases related to Glial Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1045)
# Related Disease Score Top Affiliating Genes
1 diffuse midline glioma, h3 k27m-mutant 32.1 OLIG2 BRCA2
2 gliosarcoma 31.4 PTEN OLIG2 EGFR
3 diffuse astrocytoma 30.9 OLIG2 EGFR
4 gliomatosis cerebri 30.5 PTEN EGFR
5 malignant astrocytoma 30.3 PTEN OLIG2 EGFR
6 neurofibroma 30.3 PTEN EGFR
7 central nervous system cancer 30.1 PTEN OLIG2 EGFR
8 li-fraumeni syndrome 30.0 PTEN EGFR BRCA2
9 adenocarcinoma 29.8 PTEN EGFR BRCA2
10 neurofibromatosis, type i 29.8 PTEN OLIG2 EGFR BRCA2
11 glioma 29.8 TNC PTEN EGFR BRCA2
12 mixed glioma 29.7 PTEN OLIG2 EGFR
13 giant cell glioblastoma 29.7 PTEN OLIG2 EGFR
14 anaplastic astrocytoma 29.7 PTEN OLIG2 EGFR
15 oligodendroglioma 29.7 PTEN OLIG2 EGFR
16 glioblastoma 29.6 TNC PTEN EGFR BRCA2
17 supratentorial cancer 29.5 OLIG2 EGFR
18 brain cancer 29.4 PTEN OLIG2 EGFR BRCA2
19 pancreatic ductal adenocarcinoma 29.4 PTEN EGFR BRCA2
20 endometrial adenocarcinoma 29.4 PTEN EGFR
21 suppression of tumorigenicity 12 29.2 PTEN EGFR
22 sporadic breast cancer 29.2 PTEN EGFR BRCA2
23 spinal disease 29.2 PTEN OLIG2 EGFR
24 carcinosarcoma 29.2 PTEN EGFR
25 optic nerve glioma 11.5
26 brain stem glioma 11.4
27 childhood brain stem glioma 11.4
28 brain glioma 11.4
29 optic pathway glioma 11.4
30 glioma susceptibility 2 11.4
31 glioma susceptibility 9 11.4
32 glioma susceptibility 3 11.3
33 third ventricle chordoid glioma 11.3
34 chordoid glioma 11.2
35 spinal cord glioma 11.2
36 limbic encephalitis with lgi1 antibodies 11.2
37 subependymal glioma 11.2
38 astroblastoma 11.2
39 childhood optic nerve glioma 11.1
40 mixed neuronal-glial tumor 11.1
41 angiocentric glioma 11.1
42 glioma susceptibility 6 11.1
43 glioma susceptibility 8 11.1
44 glial tumor of neuroepithelial tissue with unknown origin 11.1
45 glioma susceptibility 4 11.1
46 adult brain stem glioma 11.1
47 adult brainstem mixed glioma 11.1
48 nasal glial heterotopia 11.0
49 medulloblastoma 11.0
50 anaplastic oligodendroglioma 11.0

Graphical network of the top 20 diseases related to Glial Tumor:



Diseases related to Glial Tumor

Symptoms & Phenotypes for Glial Tumor

GenomeRNAi Phenotypes related to Glial Tumor according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Akt phosphorylation after EGF stimulation GR00204-A-2 8.62 PTEN PTPRB

MGI Mouse Phenotypes related to Glial Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.73 BRCA2 EGFR MIF OLIG2 PTEN PTPRB
2 neoplasm MP:0002006 9.55 BRCA2 EGFR MIF OLIG2 PTEN
3 nervous system MP:0003631 9.43 BRCA2 EGFR MIF OLIG2 PTEN TNC
4 normal MP:0002873 9.02 BRCA2 EGFR MIF PTEN TNC

Drugs & Therapeutics for Glial Tumor

Drugs for Glial Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 476)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Lactitol Approved, Investigational Phase 4 585-86-4 157355
3
Levetiracetam Approved Phase 4 102767-28-2 441341
4
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
5
Trametinib Approved Phase 4 871700-17-3 11707110
6
Phenobarbital Approved, Investigational Phase 4 50-06-6 4763
7
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
8
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
9
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11
Topiramate Approved Phase 4 97240-79-4 5284627
12
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
13
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
14
Rufinamide Approved Phase 4 106308-44-5 129228
15
Clobazam Approved, Illicit Phase 4 22316-47-8 2789
16
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
17 Protein Kinase Inhibitors Phase 4
18 Psychotropic Drugs Phase 4
19 Calcium, Dietary Phase 4
20 Hypoglycemic Agents Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Analgesics Phase 4
23 calcium channel blockers Phase 4
24 Sodium Channel Blockers Phase 4
25 Diuretics, Potassium Sparing Phase 4
26 Antipsychotic Agents Phase 4
27 Anti-Anxiety Agents Phase 4
28 Excitatory Amino Acid Antagonists Phase 4
29 Hypnotics and Sedatives Phase 4
30 GABA Modulators Phase 4
31 GABA Agonists Phase 4
32
Calcium Nutraceutical Phase 4 7440-70-2 271
33
leucovorin Approved Phase 3 58-05-9 6006
34
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
35
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
36
Ifosfamide Approved Phase 3 3778-73-2 3690
37
Trioxsalen Approved Phase 3 3902-71-4 5585
38
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
39
Dalteparin Approved Phase 3 9005-49-6
40
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
41
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
42
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
43
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
44
Vinblastine Approved Phase 3 865-21-4 13342 241903
45
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
46
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
47
tannic acid Approved Phase 3 1401-55-4
48
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
49
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
50
Ethanol Approved Phase 2, Phase 3 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 1185)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
3 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
4 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
5 A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma Not yet recruiting NCT04650204 Phase 4 Phenobarbital, Phenytoin, Carbamazepine, Valproate, Gabapentin, Pregabalin, Lamotrigine, Topiramate, Leviteracetam, Lacosamide, Zonisamide, Clobazam, Oxcarbezepine, Rufinamide;Perampanel
6 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
7 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
8 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
9 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
10 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
11 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
12 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
13 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
14 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
15 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
16 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
17 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
18 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
19 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
20 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
21 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
22 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
23 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
24 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma Completed NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
25 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
26 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
27 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
28 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
29 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
30 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
31 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
32 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
33 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
34 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
35 Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery Recruiting NCT04316039 Phase 2, Phase 3 Temozolomide
36 IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study Recruiting NCT03763422 Phase 3 Temozolomide
37 Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study Recruiting NCT03534050 Phase 2, Phase 3
38 A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Recruiting NCT03871257 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
39 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Recruiting NCT02455245 Phase 3 Carboplatin;Vincristine
40 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Recruiting NCT04164901 Phase 3 AG-881;Matching Placebo
41 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
42 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Recruiting NCT03633552 Phase 3 Temozolomide
43 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
44 A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial. Recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
45 Interest of Fluorescein in Fluorescence-guided Resection of Gliomas: A Randomized Study Recruiting NCT03291977 Phase 3 Fluorescéine Sodique Faure
46 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
47 A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Recruiting NCT04576117 Phase 3 Selumetinib Sulfate;Vinblastine Sulfate
48 3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial Active, not recruiting NCT01479686 Phase 3
49 DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial Active, not recruiting NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
50 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Active, not recruiting NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat

Search NIH Clinical Center for Glial Tumor

Genetic Tests for Glial Tumor

Anatomical Context for Glial Tumor

MalaCards organs/tissues related to Glial Tumor:

40
Brain, Endothelial, T Cells, Spinal Cord, Myeloid, Bone Marrow, Cortex

Publications for Glial Tumor

Articles related to Glial Tumor:

(show top 50) (show all 30496)
# Title Authors PMID Year
1
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 6
16825431 2007
2
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 6
15689453 2005
3
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 6
14670928 2004
4
A novel germline mutation of PTEN associated with brain tumours of multiple lineages. 6
12085208 2002
5
Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma. 61
32964440 2021
6
Paris saponin H inhibits the proliferation of glioma cells through the A1 and A3 adenosine receptor‑mediated pathway. 61
33537802 2021
7
Glial cell line-derived neurotrophic factor increases matrix metallopeptidase 9 and 14 expression in microglia and promotes microglia-mediated glioma progression. 61
33404121 2021
8
Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells. 61
33482186 2021
9
Effect of mtDNA depletion from C6 glioma cells and characteristics of the generated C6ρ0 cells. 61
33576438 2021
10
Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma. 61
33508290 2021
11
Increasing the accumulation of aptamer AS1411 and verapamil conjugated silver nanoparticles in tumor cells to enhance the radiosensitivity of glioma. 61
33296880 2021
12
Circ‑TOP2A acts as a ceRNA for miR‑346 and contributes to glioma progression via the modulation of sushi domain‑containing 2. 61
33537815 2021
13
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. 61
33484758 2021
14
Long Non-coding RNA MALAT1 Upregulates ZEB2 Expression to Promote Malignant Progression of Glioma by Attenuating miR-124. 61
33078370 2021
15
CAMTA1, a novel antitumor gene, regulates proliferation and the cell cycle in glioma by inhibiting AKT phosphorylation. 61
33316386 2021
16
Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan. 61
33226123 2021
17
Attention, memory, and executive functions profile in a prospective cohort of patients with malignant glioma. 61
31181969 2021
18
Anti-oncogenic activities exhibited by paracrine factors of MSCs can be mediated by modulation of KITLG and DKK1 genes in glioma SCs in vitro. 61
33575478 2021
19
Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. 61
33581781 2021
20
Sox2-dependent maintenance of mouse oligodendroglioma involves the Sox2-mediated downregulation of Cdkn2b, Ebf1, Zfp423, and Hey2. 61
32975900 2021
21
Sex differences exist in brain renin-angiotensin system-regulating aminopeptidase activities in transplacental ethyl-nitrosourea-induced gliomas. 61
33359638 2021
22
An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients. 61
32410107 2021
23
Long noncoding RNA LIFR-AS1 suppresses proliferation, migration and invasion and promotes apoptosis through modulating miR-4262/NF-κB pathway in glioma. 61
33070767 2021
24
HSP60 participates in the anti-glioma effects of curcumin. 61
33574907 2021
25
Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters. 61
32879995 2021
26
RETRACTED ARTICLE: Knock-down of LncRNA-XIST induced glioma cell death and inhibited tumorigenesis by regulating miR-137/SLC1A5 axis-mediated ROS production. 61
32036410 2021
27
Growth factors contribute to the mediation of angiogenic capacity of glioma-associated mesenchymal stem cells. 61
33552293 2021
28
New GFAP splice isoform (GFAPµ) differentially expressed in glioma translates into 21 kDa N-terminal GFAP protein. 61
33583081 2021
29
X-rays minibeam radiation therapy at a conventional irradiator: Pilot evaluation in F98-glioma bearing rats and dose calculations in a human phantom. 61
33511291 2021
30
[Corrigendum] Ouabain suppresses the growth and migration abilities of glioma U‑87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF‑1α. 61
33495805 2021
31
Transcription Factor ELF1 Activates MEIS1 Transcription and Then Regulates the GFI1/FBW7 Axis to Promote the Development of Glioma. 61
33473327 2021
32
Effect of Ras-guanine nucleotide release factor 1-mediated H-Ras/ERK signaling pathway on glioma. 61
33412149 2021
33
Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma. 61
33128602 2021
34
Phosphorylated form of pyruvate dehydrogenase α1 mediates tumor necrosis factor α-induced glioma cell migration. 61
33574915 2021
35
Insulin signaling mediates neurodegeneration in glioma. 61
33526430 2021
36
Genome-wide translation patterns in gliomas: An integrative view. 61
33321181 2021
37
Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma. 61
32821962 2021
38
Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review. 61
32840682 2021
39
Epilepsy enhance global efficiency of language networks in right temporal lobe gliomas. 61
33464718 2021
40
18F-FDG PET/CT in Anti-Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis: Typical Pattern and Follow-up. 61
33323741 2021
41
A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening. 61
33309780 2021
42
Effects of artery input function on dynamic contrast-enhanced MRI for determining grades of gliomas. 61
33332981 2021
43
Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent/Progressive Glioma Treated with High-dose Salvage Re-irradiation. 61
32917486 2021
44
Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors: A randomized controlled trial. 61
33592815 2021
45
Diffuse midline glioma presenting with central sleep apnea and pulmonary hypertension in a 4-year-old patient: a case report. 61
33006310 2021
46
XPG gene polymorphisms and glioma susceptibility: a two-centre case-control study. 61
33393424 2021
47
Stroke Mimics and Chameleons from the Radiological Viewpoint of Glioma Diagnosis. 61
33390559 2021
48
Mucosal thickening of the maxillary sinus is frequently associated with diffuse glioma patients and correlates with poor survival prognosis of GBM patients: comparative analysis to meningioma patients. 61
33537891 2021
49
Lactoferrin/phenylboronic acid-functionalized hyaluronic acid nanogels loading doxorubicin hydrochloride for targeting glioma. 61
33278970 2021
50
Microglial Exosome miR-7239-3p Promotes Glioma Progression by Regulating Circadian Genes. 61
33528793 2021

Variations for Glial Tumor

ClinVar genetic disease variations for Glial Tumor:

6 (show top 50) (show all 78)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BRCA2 NM_000059.4(BRCA2):c.92G>A (p.Trp31Ter) SNV Pathogenic 52808 rs397508045 13:32893238-32893238 13:32319101-32319101
2 BRCA2 NM_000059.4(BRCA2):c.100G>T (p.Glu34Ter) SNV Pathogenic 51041 rs80358391 13:32893246-32893246 13:32319109-32319109
3 BRCA2 NM_000059.3(BRCA2):c.1399A>T (p.Lys467Ter) SNV Pathogenic 51118 rs80358427 13:32907014-32907014 13:32332877-32332877
4 BRCA2 NM_000059.4(BRCA2):c.3109C>T (p.Gln1037Ter) SNV Pathogenic 37819 rs80358557 13:32911601-32911601 13:32337464-32337464
5 BRCA2 NM_000059.3(BRCA2):c.4243G>T (p.Glu1415Ter) SNV Pathogenic 37890 rs397507327 13:32912735-32912735 13:32338598-32338598
6 BRCA2 NM_000059.4(BRCA2):c.4965C>G (p.Tyr1655Ter) SNV Pathogenic 37936 rs80358721 13:32913457-32913457 13:32339320-32339320
7 PTEN NM_000314.7(PTEN):c.517C>T (p.Arg173Cys) SNV Pathogenic 189500 rs121913293 10:89711899-89711899 10:87952142-87952142
8 BRCA2 NM_000059.3(BRCA2):c.5791C>T (p.Gln1931Ter) SNV Pathogenic 51939 rs80358807 13:32914283-32914283 13:32340146-32340146
9 BRCA2 NM_000059.4(BRCA2):c.6656C>G (p.Ser2219Ter) SNV Pathogenic 52149 rs80358893 13:32915148-32915148 13:32341011-32341011
10 BRCA2 NM_000059.4(BRCA2):c.6952C>T (p.Arg2318Ter) SNV Pathogenic 38076 rs80358920 13:32920978-32920978 13:32346841-32346841
11 BRCA2 NM_000059.4(BRCA2):c.7879A>T (p.Ile2627Phe) SNV Pathogenic 52430 rs80359014 13:32936733-32936733 13:32362596-32362596
12 BRCA2 NM_000059.4(BRCA2):c.7988A>T (p.Glu2663Val) SNV Pathogenic 52462 rs80359031 13:32937327-32937327 13:32363190-32363190
13 BRCA2 NM_000059.4(BRCA2):c.8167G>C (p.Asp2723His) SNV Pathogenic 52515 rs41293511 13:32937506-32937506 13:32363369-32363369
14 BRCA2 NM_000059.4(BRCA2):c.8488-1G>A SNV Pathogenic 38164 rs397507404 13:32945092-32945092 13:32370955-32370955
15 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 13:32954050-32954050 13:32379913-32379913
16 BRCA2 NM_000059.4(BRCA2):c.9294C>G (p.Tyr3098Ter) SNV Pathogenic 38229 rs80359200 13:32968863-32968863 13:32394726-32394726
17 BRCA2 NM_000059.4(BRCA2):c.9382C>T (p.Arg3128Ter) SNV Pathogenic 52826 rs80359212 13:32968951-32968951 13:32394814-32394814
18 PTEN NM_000314.7(PTEN):c.253+2T>A SNV Pathogenic 468676 rs1224040268 10:89690848-89690848 10:87931091-87931091
19 PTEN NM_000314.7(PTEN):c.860C>G (p.Ser287Ter) SNV Pathogenic 216987 rs863224909 10:89720709-89720709 10:87960952-87960952
20 PTEN NM_000314.8(PTEN):c.1003C>T (p.Arg335Ter) SNV Pathogenic 7833 rs121909231 10:89720852-89720852 10:87961095-87961095
21 BRCA2 NM_000059.4(BRCA2):c.5682C>G (p.Tyr1894Ter) SNV Pathogenic 37989 rs41293497 13:32914174-32914174 13:32340037-32340037
22 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 13:32954050-32954050 13:32379913-32379913
23 BRCA2 NM_000059.4(BRCA2):c.5857G>T (p.Glu1953Ter) SNV Pathogenic 51952 rs80358814 13:32914349-32914349 13:32340212-32340212
24 BRCA2 NM_000059.4(BRCA2):c.145G>T (p.Glu49Ter) SNV Pathogenic 51129 rs80358435 13:32893291-32893291 13:32319154-32319154
25 BRCA2 NM_000059.4(BRCA2):c.7480C>T (p.Arg2494Ter) SNV Pathogenic 38099 rs80358972 13:32930609-32930609 13:32356472-32356472
26 PTEN NM_000314.7(PTEN):c.404T>A (p.Ile135Lys) SNV Likely pathogenic 428235 rs370795352 10:89692920-89692920 10:87933163-87933163
27 PTEN NM_000314.7(PTEN):c.701G>A (p.Arg234Gln) SNV risk factor 7840 rs121909235 10:89717676-89717676 10:87957919-87957919
28 BRCA2 NM_000059.4(BRCA2):c.658_659del Deletion risk factor 9342 rs80359604 13:32903605-32903606 13:32329468-32329469
29 BRCA2 NM_000059.4(BRCA2):c.5645C>G (p.Ser1882Ter) SNV risk factor 9346 rs80358785 13:32914137-32914137 13:32340000-32340000
30 PTEN NM_000314.8(PTEN):c.235G>A (p.Ala79Thr) SNV Uncertain significance 41682 rs202004587 10:89690828-89690828 10:87931071-87931071
31 PTEN NM_000314.7(PTEN):c.862G>A (p.Glu288Lys) SNV Uncertain significance 484603 rs1554825528 10:89720711-89720711 10:87960954-87960954
32 PTEN NM_000314.8(PTEN):c.892C>G (p.Gln298Glu) SNV Uncertain significance 127695 rs371387815 10:89720741-89720741 10:87960984-87960984
33 BRCA2 NM_000059.3(BRCA2):c.7625C>T (p.Thr2542Met) SNV Uncertain significance 96854 rs80358989 13:32931886-32931886 13:32357749-32357749
34 BRCA2 NM_000059.3(BRCA2):c.7051G>A (p.Ala2351Thr) SNV Uncertain significance 52256 rs80358930 13:32929041-32929041 13:32354904-32354904
35 PTEN NM_000314.8(PTEN):c.882T>G (p.Ser294Arg) SNV Uncertain significance 127693 rs143335584 10:89720731-89720731 10:87960974-87960974
36 PTEN NM_001126049.2(KLLN):c.-736G>C SNV Uncertain significance 488964 rs1554889801 10:89622980-89622980 10:87863223-87863223
37 PTEN NM_001126049.2(KLLN):c.-792C>T SNV Uncertain significance 127663 rs587779982 10:89623036-89623036 10:87863279-87863279
38 PTEN NM_001126049.2(KLLN):c.-828C>T SNV Uncertain significance 187362 rs786203674 10:89623072-89623072 10:87863315-87863315
39 PTEN NM_001126049.2(KLLN):c.-1039G>A SNV Uncertain significance 127682 rs587779999 10:89623283-89623283 10:87863526-87863526
40 PTEN NM_000314.4(PTEN):c.-868G>C SNV Uncertain significance 141949 rs587782133 10:89623358-89623358 10:87863601-87863601
41 PTEN NM_000314.7(PTEN):c.-834C>T SNV Uncertain significance 127676 rs587779994 10:89623392-89623392 10:87863635-87863635
42 PTEN NM_000314.7(PTEN):c.-821G>T SNV Uncertain significance 234510 rs587779993 10:89623405-89623405 10:87863648-87863648
43 PTEN NM_000314.7(PTEN):c.-764G>A SNV Uncertain significance 7844 rs587776674 10:89623462-89623462 10:87863705-87863705
44 BRCA2 NM_000059.3(BRCA2):c.1433C>A (p.Thr478Lys) SNV Uncertain significance 96764 rs431825282 13:32907048-32907048 13:32332911-32332911
45 BRCA2 NM_000059.3(BRCA2):c.2122T>A (p.Ser708Thr) SNV Uncertain significance 51246 rs80358488 13:32910614-32910614 13:32336477-32336477
46 BRCA2 NM_000059.3(BRCA2):c.2186T>C (p.Ile729Thr) SNV Uncertain significance 96780 rs431825296 13:32910678-32910678 13:32336541-32336541
47 BRCA2 NM_000059.4(BRCA2):c.2405A>G (p.Asn802Ser) SNV Uncertain significance 234566 rs876661089 13:32910897-32910897 13:32336760-32336760
48 BRCA2 NM_000059.3(BRCA2):c.2908G>A (p.Asp970Asn) SNV Uncertain significance 37806 rs397507295 13:32911400-32911400 13:32337263-32337263
49 BRCA2 NM_000059.3(BRCA2):c.3808G>A (p.Val1270Ile) SNV Uncertain significance 231069 rs876658938 13:32912300-32912300 13:32338163-32338163
50 BRCA2 NM_000059.4(BRCA2):c.3835A>G (p.Asn1279Asp) SNV Uncertain significance 51534 rs80358626 13:32912327-32912327 13:32338190-32338190

Expression for Glial Tumor

Search GEO for disease gene expression data for Glial Tumor.

Pathways for Glial Tumor

Pathways related to Glial Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.93 PTEN EGFR BRCA2
2 11.62 TNC PTEN EGFR
3 11.17 PTPRB EGFR
4 11.1 PTEN EGFR
5 10.99 PTEN EGFR BRCA2

GO Terms for Glial Tumor

Biological processes related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 learning or memory GO:0007611 9.26 PTEN EGFR
2 positive regulation of phosphorylation GO:0042327 9.16 MIF EGFR
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.13 PTEN MIF EGFR
4 negative regulation of cell aging GO:0090344 8.62 PTEN MIF

Molecular functions related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.02 PTEN OLIG2 MIF EGFR BRCA2

Sources for Glial Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....